2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. HMG Family

HMG Family

High Mobility Group Family

The high mobility group (HMG) proteins are a superfamily of abundant and ubiquitous nuclear proteins that bind to DNA and nucleosomes and induce structural changes in the chromatin fiber. HMG family proteins include HMGB, HMGN, and HMGA subfamilies, which are highly evolutionarily conserved nuclear proteins. The three HMG families in modulating developmental processes and tumorigenesis. As the most abundant protein among all the HMG family members and the second-most abundant protein in the nucleus, HMGB1 (also known as HMG1, HMG-1, and amphoterin) is widely expressed in mammalian cells and tissues. HMGB1 is a type of alarm signal protein that promotes the recruitment and activation of inflammation-promoting immune cells. HMG proteins is developmentally regulated and that changes in HMG protein levels alter the cellular phenotype and can lead to de

HMG Family Related Products (4):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P9928
    Alirocumab
    Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation.
    Alirocumab
  • HY-P9928A
    Alirocumab (anti-PCSK9)
    		98.24%
    Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation.
    Alirocumab (anti-PCSK9)
  • HY-P992020
    Anti-HMG1 Antibody
    		Inhibitor
    Anti-HMG1 Antibody is an anti-HMG1 antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
    Anti-HMG1 Antibody
  • HY-181546
    Ibt-DOX
    		Modulator
    Ibt-DOX is a BTK inhibitor with an IC50 of 2.89 nM. Ibt-DOX is also a targeted covalent activated chemotherapeutic agent composed of the targeting ligand Ibrutinib (HY-10997), Doxorubicin (DOX) (HY-15142A), α-MAA (HY-W017180), and a linker (HY-Y0892). Ibt-DOX specifically binds to BTK and releases DOX, synergistically achieving BTK inhibition and chemotherapeutic killing, significantly enhancing toxicity against B-cell lymphoma cells and greatly reducing the toxic side effects of DOX on BTK-negative cells. Ibt-DOX can be used in lymphoma-related research.
    Ibt-DOX